

Lixin Wan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7065677/publications.pdf>

Version: 2024-02-01

55
papers

4,608
citations

117571

34
h-index

161767

54
g-index

57
all docs

57
docs citations

57
times ranked

8279
citing authors

#	ARTICLE	IF	CITATIONS
1	SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. <i>Nature</i> , 2011, 471, 104-109.	13.7	558
2	Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus. <i>Nature</i> , 2014, 508, 541-545.	13.7	285
3	Cancer-Associated PTEN Mutants Act in a Dominant-Negative Manner to Suppress PTEN Protein Function. <i>Cell</i> , 2014, 157, 595-610.	13.5	235
4	Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis. <i>Nature Cell Biology</i> , 2013, 15, 1340-1350.	4.6	216
5	mTOR Drives Its Own Activation via SCF ^{β2} TrCP-Dependent Degradation of the mTOR Inhibitor DEPTOR. <i>Molecular Cell</i> , 2011, 44, 290-303.	4.5	212
6	Targeting Cdc20 as a novel cancer therapeutic strategy. , 2015, 151, 141-151.		194
7	Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway. <i>Science</i> , 2019, 364, .	6.0	194
8	Phosphorylation by Casein Kinase I Promotes the Turnover of the Mdm2 Oncoprotein via the SCF ^{β2} -TRCP Ubiquitin Ligase. <i>Cancer Cell</i> , 2010, 18, 147-159.	7.7	182
9	Acetylation-Dependent Regulation of Skp2 Function. <i>Cell</i> , 2012, 150, 179-193.	13.5	180
10	Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function. <i>Molecular Cell</i> , 2018, 69, 279-291.e5.	4.5	138
11	Tumor suppressor functions of FBW7 in cancer development and progression. <i>FEBS Letters</i> , 2012, 586, 1409-1418.	1.3	136
12	MC1R Is a Potent Regulator of PTEN after UV Exposure in Melanocytes. <i>Molecular Cell</i> , 2013, 51, 409-422.	4.5	122
13	RAF-MEK-ERK pathway in cancer evolution and treatment. <i>Seminars in Cancer Biology</i> , 2022, 85, 123-154.	4.3	113
14	APCCdc20 Suppresses Apoptosis through Targeting Bim for Ubiquitination and Destruction. <i>Developmental Cell</i> , 2014, 29, 377-391.	3.1	110
15	Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade. <i>Molecular Cell</i> , 2021, 81, 2317-2331.e6.	4.5	97
16	Cdc20: A Potential Novel Therapeutic Target for Cancer Treatment. <i>Current Pharmaceutical Design</i> , 2013, 19, 3210-3214.	0.9	95
17	Cdh1 Regulates Osteoblast Function through an APC/C-Independent Modulation of Smurf1. <i>Molecular Cell</i> , 2011, 44, 721-733.	4.5	91
18	SCF ^{β2} -TRCP suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. <i>Journal of Experimental Medicine</i> , 2012, 209, 1289-1307.	4.2	85

#	ARTICLE	IF	CITATIONS
19	Rictor Forms a Complex with Cullin-1 to Promote SGK1 Ubiquitination and Destruction. <i>Molecular Cell</i> , 2010, 39, 797-808.	4.5	84
20	FBW7 Loss Promotes Chromosomal Instability and Tumorigenesis via Cyclin E1/CDK2-Mediated Phosphorylation of CENP-A. <i>Cancer Research</i> , 2017, 77, 4881-4893.	0.4	68
21	A covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination. <i>EMBO Journal</i> , 2017, 36, 1243-1260.	3.5	67
22	PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas. <i>Journal of Clinical Investigation</i> , 2018, 128, 5517-5530.	3.9	67
23	SCF-Mediated Cdh1 Degradation Defines a Negative Feedback System that Coordinates Cell-Cycle Progression. <i>Cell Reports</i> , 2013, 4, 803-816.	2.9	65
24	Cdh1 Regulates Cell Cycle through Modulating the Claspin/Chk1 and the Rb/E2F1 Pathways. <i>Molecular Biology of the Cell</i> , 2009, 20, 3305-3316.	0.9	64
25	Functional characterization of Anaphase Promoting Complex/Cyclosome (APC/C) E3 ubiquitin ligases in tumorigenesis. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1845, 277-293.	3.3	64
26	K27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling. <i>Nature Communications</i> , 2019, 10, 1870.	5.8	61
27	HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy. <i>Cancer Research</i> , 2019, 79, 2947-2961.	0.4	59
28	The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function. <i>Cancer Discovery</i> , 2017, 7, 424-441.	7.7	57
29	Skp2 dictates cell cycle-dependent metabolic oscillation between glycolysis and TCA cycle. <i>Cell Research</i> , 2021, 31, 80-93.	5.7	51
30	SCFFBW7-mediated degradation of Brg1 suppresses gastric cancer metastasis. <i>Nature Communications</i> , 2018, 9, 3569.	5.8	49
31	SCF ^{β2} -TRCP-mediated degradation of NEDD4 inhibits tumorigenesis through modulating the PTEN/Akt signaling pathway. <i>Oncotarget</i> , 2014, 5, 1026-1037.	0.8	45
32	SCF ^{β2} -TRCP targets MTSS1 for ubiquitination-mediated destruction to regulate cancer cell proliferation and migration. <i>Oncotarget</i> , 2013, 4, 2339-2353.	0.8	44
33	Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation. <i>Cancer Letters</i> , 2017, 385, 207-214.	3.2	43
34	The two faces of FBW7 in cancer drug resistance. <i>BioEssays</i> , 2011, 33, 851-859.	1.2	39
35	Deregulated PP1 [±] phosphatase activity towards MAPK activation is antagonized by a tumor suppressive failsafe mechanism. <i>Nature Communications</i> , 2018, 9, 159.	5.8	39
36	ITCH as a potential therapeutic target in human cancers. <i>Seminars in Cancer Biology</i> , 2020, 67, 117-130.	4.3	39

#	ARTICLE	IF	CITATIONS
37	SCF ^{Î2} -TRCP promotes cell growth by targeting PR-Set7/Set8 for degradation. <i>Nature Communications</i> , 2015, 6, 10185.	5.8	37
38	Monoubiquitination Inhibits the Actin Bundling Activity of Fascin. <i>Journal of Biological Chemistry</i> , 2016, 291, 27323-27333.	1.6	34
39	<i>PTPN11</i> Plays Oncogenic Roles and Is a Therapeutic Target for <i>BRAF</i> Wild-Type Melanomas. <i>Molecular Cancer Research</i> , 2019, 17, 583-593.	1.5	34
40	Cdh1 inhibits WWP2-mediated ubiquitination of PTEN to suppress tumorigenesis in an APC-independent manner. <i>Cell Discovery</i> , 2016, 2, 15044.	3.1	33
41	Smurf1 regulation of DAB2IP controls cell proliferation and migration. <i>Oncotarget</i> , 2016, 7, 26057-26069.	0.8	28
42	Regulation of APC/Cdh1 E3 ligase activity by the Fbw7/cyclin E signaling axis contributes to the tumor suppressor function of Fbw7. <i>Cell Research</i> , 2013, 23, 947-961.	5.7	27
43	DNA damage-induced activation of ATM promotes Î2-TRCP-mediated Mdm2 ubiquitination and destruction. <i>Oncotarget</i> , 2012, 3, 1026-1035.	0.8	27
44	Cdh1 regulates craniofacial development via APC-dependent ubiquitination and activation of Goosecoid. <i>Cell Research</i> , 2016, 26, 699-712.	5.7	25
45	The E3 ligase APC/C ^{Cdh1} promotes ubiquitylation-mediated proteolysis of PAX3 to suppress melanocyte proliferation and melanoma growth. <i>Science Signaling</i> , 2015, 8, ra87.	1.6	21
46	IRTKS is correlated with progression and survival time of patients with gastric cancer. <i>Gut</i> , 2018, 67, 1400-1409.	6.1	20
47	Interplay between c-Src and the APC/C co-activator Cdh1 regulates mammary tumorigenesis. <i>Nature Communications</i> , 2019, 10, 3716.	5.8	19
48	Phosphorylation of Rictor at Thr1135 impairs the Rictor/Cullin-1 complex to ubiquitinate SGK1. <i>Protein and Cell</i> , 2010, 1, 881-885.	4.8	16
49	Acetylation-dependent regulation of BRAF oncogenic function. <i>Cell Reports</i> , 2022, 38, 110250.	2.9	13
50	The CREB-binding protein inhibitor ICG-001: a promising therapeutic strategy in sporadic meningioma with NF2 mutations. <i>Neuro-Oncology Advances</i> , 2020, 2, vdz055.	0.4	9
51	Palmitoylation modification of GÎ±o depresses its susceptibility to GAP-43 activation. <i>International Journal of Biochemistry and Cell Biology</i> , 2009, 41, 1495-1501.	1.2	7
52	Characterization of the ATPase activity of a novel chimeric fusion protein consisting of the two nucleotide binding domains of MRP1. <i>Archives of Biochemistry and Biophysics</i> , 2009, 485, 102-108.	1.4	3
53	AMPK lifts the PRC2-implemented gene repression. <i>Molecular and Cellular Oncology</i> , 2018, 5, e1441632.	0.3	2
54	Cycling for renewal: Cell cycle machinery maintains prostate cancer stem-like cells. <i>EBioMedicine</i> , 2019, 42, 24-25.	2.7	2

#	ARTICLE	IF	CITATIONS
55	Pharmacoproteomics Identifies PLK1 As Vulnerability for Aggressive B-Cell Lymphomas. Blood, 2018, 132, 2853-2853.	0.6	0